Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment.

Monath TP, Fast PE, Modjarrad K, Clarke DK, Martin BK, Fusco J, Nichols R, Heppner DG, Simon JK, Dubey S, Troth SP, Wolf J, Singh V, Coller BA, Robertson JS; Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG).

Vaccine X. 2019 Jan 29;1:100009. doi: 10.1016/j.jvacx.2019.100009. eCollection 2019 Apr 11.

2.

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.

Modjarrad K, Roberts CC, Mills KT, Castellano AR, Paolino K, Muthumani K, Reuschel EL, Robb ML, Racine T, Oh MD, Lamarre C, Zaidi FI, Boyer J, Kudchodkar SB, Jeong M, Darden JM, Park YK, Scott PT, Remigio C, Parikh AP, Wise MC, Patel A, Duperret EK, Kim KY, Choi H, White S, Bagarazzi M, May JM, Kane D, Lee H, Kobinger G, Michael NL, Weiner DB, Thomas SJ, Maslow JN.

Lancet Infect Dis. 2019 Sep;19(9):1013-1022. doi: 10.1016/S1473-3099(19)30266-X. Epub 2019 Jul 24.

PMID:
31351922
3.

Zika Virus in Rectal Swab Samples.

Bôtto-Menezes CHA, Neto AM, Calvet GA, Kara EO, Lacerda MVG, Castilho MDC, Ströher U, Antunes de Brito CA, Modjarrad K, Broutet N, Brasil P, Bispo de Filippis AM, Franca RFO; ZIKABRA Study Team.

Emerg Infect Dis. 2019 May;25(5):951-954. doi: 10.3201/eid2505.180904.

4.

Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.

Crowell TA, Colby DJ, Pinyakorn S, Sacdalan C, Pagliuzza A, Intasan J, Benjapornpong K, Tangnaree K, Chomchey N, Kroon E, de Souza MS, Tovanabutra S, Rolland M, Eller MA, Paquin-Proulx D, Bolton DL, Tokarev A, Thomas R, Takata H, Trautmann L, Krebs SJ, Modjarrad K, McDermott AB, Bailer RT, Doria-Rose N, Patel B, Gorelick RJ, Fullmer BA, Schuetz A, Grandin PV, O'Connell RJ, Ledgerwood JE, Graham BS, Tressler R, Mascola JR, Chomont N, Michael NL, Robb ML, Phanuphak N, Ananworanich J; RV397 Study Group.

Lancet HIV. 2019 May;6(5):e297-e306. doi: 10.1016/S2352-3018(19)30053-0. Epub 2019 Apr 15.

PMID:
31000477
5.

Development and characterization of a Zaire Ebola (ZEBOV) specific IgM ELISA.

Atre T, Phillips RL, Modjarrad K, Regules JA, Bergmann-Leitner ES.

J Immunol Methods. 2019 May;468:29-34. doi: 10.1016/j.jim.2019.03.008. Epub 2019 Mar 22.

PMID:
30910536
6.

Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas.

Adney DR, Wang L, van Doremalen N, Shi W, Zhang Y, Kong WP, Miller MR, Bushmaker T, Scott D, de Wit E, Modjarrad K, Petrovsky N, Graham BS, Bowen RA, Munster VJ.

Viruses. 2019 Mar 2;11(3). pii: E212. doi: 10.3390/v11030212.

7.

Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape.

Wang L, Shi W, Chappell JD, Joyce MG, Zhang Y, Kanekiyo M, Becker MM, van Doremalen N, Fischer R, Wang N, Corbett KS, Choe M, Mason RD, Van Galen JG, Zhou T, Saunders KO, Tatti KM, Haynes LM, Kwong PD, Modjarrad K, Kong WP, McLellan JS, Denison MR, Munster VJ, Mascola JR, Graham BS.

J Virol. 2018 Apr 27;92(10). pii: e02002-17. doi: 10.1128/JVI.02002-17. Print 2018 May 15.

8.

Respiratory syncytial virus vaccine research and development: World Health Organization technological roadmap and preferred product characteristics.

Vekemans J, Moorthy V, Giersing B, Friede M, Hombach J, Arora N, Modjarrad K, Smith PG, Karron R, Graham B, Kaslow D.

Vaccine. 2018 Jan 25. pii: S0264-410X(17)31364-6. doi: 10.1016/j.vaccine.2017.09.092. [Epub ahead of print] Review.

PMID:
29395536
9.

Study on the persistence of Zika virus (ZIKV) in body fluids of patients with ZIKV infection in Brazil.

Calvet GA, Kara EO, Giozza SP, Bôtto-Menezes CHA, Gaillard P, de Oliveira Franca RF, de Lacerda MVG, da Costa Castilho M, Brasil P, de Sequeira PC, de Mello MB, Bermudez XPD, Modjarrad K, Meurant R, Landoulsi S, Benzaken AS, de Filippis AMB, Broutet NJN; ZIKABRA Study Team.

BMC Infect Dis. 2018 Jan 22;18(1):49. doi: 10.1186/s12879-018-2965-4.

10.

Durability and correlates of vaccine protection against Zika virus in rhesus monkeys.

Abbink P, Larocca RA, Visitsunthorn K, Boyd M, De La Barrera RA, Gromowski GD, Kirilova M, Peterson R, Li Z, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Chandrashekar A, Jetton D, Mojta S, Gandhi P, LeSuer J, Khatiwada S, Lewis MG, Modjarrad K, Jarman RG, Eckels KH, Thomas SJ, Michael NL, Barouch DH.

Sci Transl Med. 2017 Dec 13;9(420). pii: eaao4163. doi: 10.1126/scitranslmed.aao4163. Erratum in: Sci Transl Med. 2018 Jul 18;10(450):.

11.

Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.

Modjarrad K, Lin L, George SL, Stephenson KE, Eckels KH, De La Barrera RA, Jarman RG, Sondergaard E, Tennant J, Ansel JL, Mills K, Koren M, Robb ML, Barrett J, Thompson J, Kosel AE, Dawson P, Hale A, Tan CS, Walsh SR, Meyer KE, Brien J, Crowell TA, Blazevic A, Mosby K, Larocca RA, Abbink P, Boyd M, Bricault CA, Seaman MS, Basil A, Walsh M, Tonwe V, Hoft DF, Thomas SJ, Barouch DH, Michael NL.

Lancet. 2018 Feb 10;391(10120):563-571. doi: 10.1016/S0140-6736(17)33106-9. Epub 2017 Dec 5.

12.

Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein.

Tian D, Battles MB, Moin SM, Chen M, Modjarrad K, Kumar A, Kanekiyo M, Graepel KW, Taher NM, Hotard AL, Moore ML, Zhao M, Zheng ZZ, Xia NS, McLellan JS, Graham BS.

Nat Commun. 2017 Nov 30;8(1):1877. doi: 10.1038/s41467-017-01858-w.

14.

Are you PEPped and PrEPped for travel? Risk mitigation of HIV infection for travelers.

Brett-Major DM, Scott PT, Crowell TA, Polyak CS, Modjarrad K, Robb ML, Blazes DL.

Trop Dis Travel Med Vaccines. 2016 Nov 28;2:25. doi: 10.1186/s40794-016-0042-9. eCollection 2016. Review.

15.

Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.

McCracken MK, Gromowski GD, Friberg HL, Lin X, Abbink P, De La Barrera R, Eckles KH, Garver LS, Boyd M, Jetton D, Barouch DH, Wise MC, Lewis BS, Currier JR, Modjarrad K, Milazzo M, Liu M, Mullins AB, Putnak JR, Michael NL, Jarman RG, Thomas SJ.

PLoS Pathog. 2017 Aug 3;13(8):e1006487. doi: 10.1371/journal.ppat.1006487. eCollection 2017 Aug.

16.

Opium trade and the spread of HIV in the Golden Crescent.

Farooq SA, Rasooly MH, Abidi SH, Modjarrad K, Ali S.

Harm Reduct J. 2017 Jul 21;14(1):47. doi: 10.1186/s12954-017-0170-1. Review.

17.

T Cell Immunity and Zika Virus Vaccine Development.

Lima NS, Rolland M, Modjarrad K, Trautmann L.

Trends Immunol. 2017 Aug;38(8):594-605. doi: 10.1016/j.it.2017.05.004. Epub 2017 Jun 1. Review.

PMID:
28579320
18.

Discovery of a Prefusion Respiratory Syncytial Virus F-Specific Monoclonal Antibody That Provides Greater In Vivo Protection than the Murine Precursor of Palivizumab.

Zhao M, Zheng ZZ, Chen M, Modjarrad K, Zhang W, Zhan LT, Cao JL, Sun YP, McLellan JS, Graham BS, Xia NS.

J Virol. 2017 Jul 12;91(15). pii: e00176-17. doi: 10.1128/JVI.00176-17. Print 2017 Aug 1.

19.

Reply to Lipsitch.

Kilianski A, Nuzzo JB, Modjarrad K.

J Infect Dis. 2016 Oct 15;214(8):1285-6. doi: 10.1093/infdis/jiw349. Epub 2016 Aug 8. No abstract available.

PMID:
27503366
20.

Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.

Abbink P, Larocca RA, De La Barrera RA, Bricault CA, Moseley ET, Boyd M, Kirilova M, Li Z, Ng'ang'a D, Nanayakkara O, Nityanandam R, Mercado NB, Borducchi EN, Agarwal A, Brinkman AL, Cabral C, Chandrashekar A, Giglio PB, Jetton D, Jimenez J, Lee BC, Mojta S, Molloy K, Shetty M, Neubauer GH, Stephenson KE, Peron JP, Zanotto PM, Misamore J, Finneyfrock B, Lewis MG, Alter G, Modjarrad K, Jarman RG, Eckels KH, Michael NL, Thomas SJ, Barouch DH.

Science. 2016 Sep 9;353(6304):1129-32. doi: 10.1126/science.aah6157. Epub 2016 Aug 4.

21.

Toward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.

Excler JL, Delvecchio CJ, Wiley RE, Williams M, Yoon IK, Modjarrad K, Boujelal M, Moorthy VS, Hersi AS, Kim JH; MERS-CoV Vaccine Working Group.

Emerg Infect Dis. 2016 Aug;22(8). doi: 10.3201/eid2208.160229.

22.

A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation.

Modjarrad K, Moorthy VS, Ben Embarek P, Van Kerkhove M, Kim J, Kieny MP.

Nat Med. 2016 Jul 7;22(7):701-5. doi: 10.1038/nm.4131. No abstract available.

PMID:
27387881
23.

The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC).

Giersing BK, Modjarrad K, Kaslow DC, Okwo-Bele JM, Moorthy VS.

Vaccine. 2016 Jun 3;34(26):2863-2864. doi: 10.1016/j.vaccine.2016.04.041. Epub 2016 Apr 21. No abstract available.

24.

Status of vaccine research and development of vaccines for Staphylococcus aureus.

Giersing BK, Dastgheyb SS, Modjarrad K, Moorthy V.

Vaccine. 2016 Jun 3;34(26):2962-2966. doi: 10.1016/j.vaccine.2016.03.110. Epub 2016 Apr 19. Review.

25.

MERS-CoV vaccine candidates in development: The current landscape.

Modjarrad K.

Vaccine. 2016 Jun 3;34(26):2982-2987. doi: 10.1016/j.vaccine.2016.03.104. Epub 2016 Apr 12. Review.

26.

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015.

Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS; WHO Product Development for Vaccines Advisory Committee; WHO Product Development for Vaccines Product Development Advisory Committee:.

Vaccine. 2016 Jun 3;34(26):2865-2869. doi: 10.1016/j.vaccine.2016.02.078. Epub 2016 Mar 15.

27.
28.

Developing Global Norms for Sharing Data and Results during Public Health Emergencies.

Modjarrad K, Moorthy VS, Millett P, Gsell PS, Roth C, Kieny MP.

PLoS Med. 2016 Jan 5;13(1):e1001935. doi: 10.1371/journal.pmed.1001935. eCollection 2016 Jan. Review. No abstract available.

29.

Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.

Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Al-Hameed FM, Taha Y, Shindo N, Whitehead J, Merson L, AlJohani S, Al-Khairy K, Carson G, Luke TC, Hensley L, Al-Dawood A, Al-Qahtani S, Modjarrad K, Sadat M, Rohde G, Leport C, Fowler R.

Springerplus. 2015 Nov 19;4:709. doi: 10.1186/s40064-015-1490-9. eCollection 2015.

30.

Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.

Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS.

Sci Transl Med. 2015 Oct 14;7(309):309ra162. doi: 10.1126/scitranslmed.aac4241.

31.

Gain-of-Function Research and the Relevance to Clinical Practice.

Kilianski A, Nuzzo JB, Modjarrad K.

J Infect Dis. 2016 May 1;213(9):1364-9. doi: 10.1093/infdis/jiv473. Epub 2015 Sep 27. Review.

PMID:
26416657
32.

Evaluation of candidate vaccine approaches for MERS-CoV.

Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, Lees CR, Zhou T, Yassine HM, Kanekiyo M, Yang ZY, Chen X, Becker MM, Freeman M, Vogel L, Johnson JC, Olinger G, Todd JP, Bagci U, Solomon J, Mollura DJ, Hensley L, Jahrling P, Denison MR, Rao SS, Subbarao K, Kwong PD, Mascola JR, Kong WP, Graham BS.

Nat Commun. 2015 Jul 28;6:7712. doi: 10.1038/ncomms8712.

33.

WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.

Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS; WHO RSV Vaccine Consultation Expert Group.

Vaccine. 2016 Jan 4;34(2):190-197. doi: 10.1016/j.vaccine.2015.05.093. Epub 2015 Jun 20.

34.

Multiple co-circulating HIV-1 subtypes in the Middle East and North Africa.

Rolland M, Modjarrad K.

AIDS. 2015 Jul 17;29(11):1417-9. doi: 10.1097/QAD.0000000000000764.

35.

Novel antigens for RSV vaccines.

Graham BS, Modjarrad K, McLellan JS.

Curr Opin Immunol. 2015 Aug;35:30-8. doi: 10.1016/j.coi.2015.04.005. Epub 2015 Jun 10. Review.

36.

HIV and helminths: time for a new direction.

Modjarrad K.

Lancet Infect Dis. 2013 Oct;13(10):835. doi: 10.1016/S1473-3099(13)70239-1. No abstract available.

PMID:
24070561
37.

Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody.

McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS.

Science. 2013 May 31;340(6136):1113-7. doi: 10.1126/science.1234914. Epub 2013 Apr 25.

38.

AIDS epidemic: Iran needs global support to fight HIV.

Modjarrad K, Mohraz M, Madani N.

Nature. 2013 Feb 21;494(7437):314. doi: 10.1038/494314c. No abstract available.

PMID:
23426315
39.

An addition to the effect of treating co-infections on HIV-1 viral load.

Modjarrad K, Vermund SH.

Lancet Infect Dis. 2011 Feb;11(2):81. doi: 10.1016/S1473-3099(11)70013-5. No abstract available.

PMID:
21272789
40.

A comparison of HIV detection rates using routine opt-out provider-initiated HIV testing and counseling versus a standard of care approach in a rural African setting.

Silvestri DM, Modjarrad K, Blevins ML, Halale E, Vermund SH, McKinzie JP.

J Acquir Immune Defic Syndr. 2011 Jan 1;56(1):e9-32.

41.

Effect of treating co-infections on HIV-1 viral load: a systematic review.

Modjarrad K, Vermund SH.

Lancet Infect Dis. 2010 Jul;10(7):455-63. doi: 10.1016/S1473-3099(10)70093-1. Review.

42.
43.

Which helminth coinfections really affect HIV disease progression?

Modjarrad K.

AIDS. 2009 Jan 14;23(2):276-7; author reply 277-8. doi: 10.1097/QAD.0b013e32831fc692. No abstract available.

PMID:
19098502
44.

Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression.

Modjarrad K, Chamot E, Vermund SH.

AIDS. 2008 Oct 18;22(16):2179-85. doi: 10.1097/QAD.0b013e328312c756. Review.

45.

Association between upper extremity injuries and side airbag availability.

McGwin G Jr, Modjarrad K, Duma S, Rue LW 3rd.

J Trauma. 2008 May;64(5):1297-301. doi: 10.1097/TA.0b013e3181271b21.

PMID:
18469653
46.

Body mass index affects the need for and the duration of mechanical ventilation after thoracic trauma.

Reiff DA, Hipp G, McGwin G Jr, Modjarrad K, MacLennan PA, Rue LW 3rd.

J Trauma. 2007 Jun;62(6):1432-5.

PMID:
17563661
47.

The descriptive epidemiology of intentional burns in the United States: an analysis of the National Burn Repository.

Modjarrad K, McGwin G Jr, Cross JM, Rue LW 3rd.

Burns. 2007 Nov;33(7):828-32. Epub 2007 May 24.

PMID:
17531393
48.

Prevalence of transportation safety measures portrayed in primetime US television programs and commercials.

McGwin G Jr, Modjarrad K, Reiland A, Tanner S, Rue LW 3rd.

Inj Prev. 2006 Dec;12(6):400-3.

49.

Effect of cataract surgery on falls and mobility in independently living older adults.

McGwin G Jr, Gewant HD, Modjarrad K, Hall TA, Owsley C.

J Am Geriatr Soc. 2006 Jul;54(7):1089-94.

PMID:
16866680
50.

Supplemental Content

Loading ...
Support Center